Market Place
Sourcing Support
Immutep Reports New Data in Head & Neck Cancer at ESMO 2024
12 Dec 2024 //
GLOBENEWSWIRE
Immutep Initiates TACTI-004 Phase III Trial in 1st Line NSCLC
10 Dec 2024 //
GLOBENEWSWIRE
Positive Phase II Data in Soft Tissue Sarcoma Presented at CTOS
14 Nov 2024 //
GLOBENEWSWIRE
Immutep’s Efti Shows Survival Data from INSIGHT-003 in NSCLC
14 Nov 2024 //
GLOBENEWSWIRE
Immutep Quarterly Activities Report Q1 FY25
29 Oct 2024 //
GLOBENEWSWIRE
Immutep Presents Phase IIb Data in Head and Neck Cancer at ESMO
28 Oct 2024 //
#N/A
Immutep Advances First-in-Human Study Of IMP761 To Dose Escalation
17 Oct 2024 //
GLOBENEWSWIRE
Immutep to Participate in the 2024 Maxim Healthcare Virtual Summit
10 Oct 2024 //
GLOBENEWSWIRE
Immutep Completes AIPAC-003 Trial Enrollment For Breast Cancer
03 Oct 2024 //
GLOBENEWSWIRE
Immutep Receives A$3.6 million R&D Tax Incentive from Government
24 Sep 2024 //
GLOBENEWSWIRE
New Efti Combination Data To Be Presented For Sarcoma
18 Sep 2024 //
GLOBENEWSWIRE
Immutep`s Efti Shows Positive Results In Head And Neck Cancer
16 Sep 2024 //
GLOBENEWSWIRE
Immutep`s Head & Neck Cancer Abstract Selected For ESMO 2024
20 Aug 2024 //
GLOBENEWSWIRE
Immutep Doses First Participant In Phase I Study Of IMP761 LAG-3 Antibody
14 Aug 2024 //
GLOBENEWSWIRE
Immutep to Participate in Upcoming Investor Conferences
07 Aug 2024 //
GLOBENEWSWIRE
Immutep Quarterly Activities Report Q4 FY24
31 Jul 2024 //
GLOBENEWSWIRE
Immutep Reports Successful FDA Meeting On Phase III NSCLC Trial Design
22 Jul 2024 //
GLOBENEWSWIRE
Immutep Cleared For Phase I Study Of LAG-3 Agonist Antibody
17 Jul 2024 //
GLOBENEWSWIRE
Immutep’s LAG-3 drug scores in Phase 2b head and neck cancer test
13 Jul 2024 //
PRESS RELEASE
Immutep Reports Positive Results In First Line Head And Neck Cancer
11 Jul 2024 //
GLOBENEWSWIRE
Immutep Pursues Cancer Therapy Path With Subgroup Data And Caveats
11 Jul 2024 //
FIERCE BIOTECH
Immutep To Present Clinical Results At ESMO Virtual Plenary And Host Webcast
03 Jul 2024 //
GLOBENEWSWIRE
Immutep Signs License Agreement with Cardiff University for Next-Gen Cancer Drug
26 Jun 2024 //
BIOSPECTRUM ASIA
Immutep Signs Exclusive License Agreement for Next-Gen Anti-LAG-3 Molecules
25 Jun 2024 //
GLOBENEWSWIRE
Immutep: Completes Institutional Placement & Entitlement Offer
05 Jun 2024 //
GLOBENEWSWIRE
Immutep, Merck Collaborate On Efti Plus KEYTRUDA In Pivotal Phase III
02 Jun 2024 //
GLOBENEWSWIRE
Immutep Presents Data from Safety Lead-in Phase of AIPAC-003 at ESMO Breast 2024
15 May 2024 //
GLOBENEWSWIRE
Immutep: Positive IO Combo Data In Soft Tissue Sarcoma Phase 2
02 May 2024 //
GLOBENEWSWIRE
Immutep Quarterly Activities Report Q3 FY24
29 Apr 2024 //
GLOBENEWSWIRE
Immutep Announces Positive Preliminary Topline Results from TACTI-003 Cohort B
24 Apr 2024 //
GLOBENEWSWIRE
Immutep Taps Institute For First-In-Human Phase 1 Study Of IMP761
18 Apr 2024 //
GLOBENEWSWIRE
Immutep Receives Positive Feedback for TACTI-004 Lung Cancer Trial
17 Apr 2024 //
GLOBENEWSWIRE
Immutep Announces First Clinical Data from 90mg Dosing of Efti
05 Mar 2024 //
GLOBENEWSWIRE
Immutep Quarterly Activities Report Q2 FY24
30 Jan 2024 //
GLOBENEWSWIRE
Immutep Receives Constructive Regulatory Feedback on TACTI-004 Trial
21 Dec 2023 //
GLOBENEWSWIRE
Immutep Announces Site Expansion for INSIGHT-003 Phase I Trial
22 Nov 2023 //
GLOBENEWSWIRE
Immutep Completes Enrollment in TACTI-003 Phase IIb Trial of Efti and KEYTRUDA
09 Nov 2023 //
GLOBENEWSWIRE
Immutep Announces New Biomarker Data from TACTI-002 Phase II
03 Nov 2023 //
GLOBENEWSWIRE
Immutep to Participate in November Investor Events
02 Nov 2023 //
GLOBENEWSWIRE
Immutep Quarterly Activities Report Q1 FY24
31 Oct 2023 //
GLOBENEWSWIRE
Immutep receives ~A$1.13 million R&D Tax Incentive
25 Oct 2023 //
GLOBENEWSWIRE
Immutep™s Efti Generates Excellent Overall Survival Benefit in NSCLC
23 Oct 2023 //
GLOBENEWSWIRE
Immutep Announces Publication of Abstracts at ESMO Congress 2023
16 Oct 2023 //
GLOBENEWSWIRE
Immutep Announces Abstract Accepted for Presentation at SITC
03 Oct 2023 //
GLOBENEWSWIRE
Commercial Manufacturing of Eftilagimod at 2000L Scale Granted Authorization
21 Sep 2023 //
GLOBENEWSWIRE
Immutep to Participate in September Investor Conferences
05 Sep 2023 //
GLOBENEWSWIRE
Immutep Receives Positive Scientific Advice from European Medicines Agency
01 Aug 2023 //
GLOBENEWSWIRE
Immutep to Present Overall Survival Data in 1st Line Non-Small Cell Lung Cancer
31 Jul 2023 //
GLOBENEWSWIRE
Immutep Quarterly Activities Report Q4 FY23
31 Jul 2023 //
GLOBENEWSWIRE
First Patient Dosed in Chemotherapy-Free Triple Combination Phase II Trial
28 Jul 2023 //
GLOBENEWSWIRE
Immutep picks up more funds for LAG-3 oncology and autoimmune studies
28 Jun 2023 //
ENDPTS
Immutep Completes A$80 Million Capital Raise
27 Jun 2023 //
GLOBENEWSWIRE
Immutep Secures Third United States Patent for Eftilagimod Alpha in Combination
27 Jun 2023 //
GLOBENEWSWIRE
Immutep to Participate at the Jefferies Healthcare Conference
07 Jun 2023 //
GLOBENEWSWIRE
Immutep Reports Final Positive Data in 2nd Line Head at ASCO 2023 Annual Meeting
05 Jun 2023 //
GLOBENEWSWIRE
Immutep Completes Institutional Placement of its Entitlement Offer
02 Jun 2023 //
GLOBENEWSWIRE
Immutep Selects Charles River Laboratories for IMP761’s GLP Toxicology Study
30 May 2023 //
GLOBENEWSWIRE
Immutep Announces Publication of Abstracts for ASCO 2023 Annual Meeting
26 May 2023 //
GLOBENEWSWIRE
Immutep Doses First Patient in Phase II/III Trial for Metastatic Breast Cancer
25 May 2023 //
GLOBENEWSWIRE
Immutep Efti in Combination with Pembrolizumab Achieves Benefit in 1L NSCLC
17 May 2023 //
GLOBENEWSWIRE
